PTEN and cancer: Concerning positive PTEN expression in CRC cases versus controls, 32% of patients showed 1+ PTEN expression (weakly positive), 20% showed 2+ PTEN expression (moderately positive), and 20% showed 3+ PTEN expression (strong positive); versus 8% of controls showed 1+ PTEN expression, 32% showed 2+ PTEN expression and 60% showed 3+ PTEN expression; indicating that immunohistochemical PTEN expression could have a protective role and loss of its expression carry high risk of cancer development with significant p value (p=0.001) (Table 4).